Good time to revisit the mnd webinar, suggests it could finish after cohort 3 and progress to phase 2 trial this quarter, eager and confident of running it here to benefit our own. Do we have a good enough stash of tablets I can hear you asking cashtrain, I hope we do. They talk about targeting other neurological diseases like Parkinson’s and comment on the favourable safety profile of MPL compared to the European trial with Rapamycin. First time I watched it since and appreciated it more since the latest news. This has been a great partnership for Pharmaust let’s hope its a long one.
https://www.pharmaust.com/phamaust-webinar/
Ann: MND Biomarkers and Pharmacodynamics Results, page-129
-
- There are more pages in this discussion • 268 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $82.65M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.8¢ | $151.1K | 877.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 54714 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 371375 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |